Doxorubicin liposome formulation gains marketing approval.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin